Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher

Contributed by: Business Wire

Logo

Tags

Mental Health

Research

FDA

Clinical Trials

Biotechnology

Alternative Medicine

Health

Pharmaceutical

Science

More Like This

Compass Pathways to Announce New Clinical Data from Two Ongoing Phase 3 Trials

Compass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic Treatments

Compass Pathways Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Highlights

Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression

Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression

Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression

Compass Pathways Announces Dosing Complete for All Participants in Part A of Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression

Compass Pathways Announces U.S Grant Program for the Creation of Post-Approval COMP360 Provider Training